PCV21 vaccine

BIOLOGICAL5 trials

Sponsors

Sanofi Pasteur, a Sanofi Company, Sanofi

Conditions

Healthy VolunteersPneumococcal Immunization

Phase 3

Study of a 4-Dose Regimen of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of Age

Active, not recruitingNCT06736041

Sanofi Pasteur, a Sanofi CompanyPneumococcal Immunization

Start: 2024-12-18End: 2027-05-17Updated: 2026-02-18

Study of Mixed Vaccination Schedules With a 21-valent Pneumococcal Conjugate Vaccine and a 20-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of Age

Active, not recruitingNCT06824181

SanofiPneumococcal Immunization

Start: 2025-02-27End: 2027-09-10Updated: 2026-02-13

Study of the Safety of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of Age

RecruitingNCT06824194

SanofiPneumococcal Immunization

Start: 2025-02-18End: 2027-05-12Target: 2320Updated: 2026-03-03

Study of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of Age

Active, not recruitingNCT06975878

SanofiHealthy Volunteers, Pneumococcal Immunization

Start: 2025-05-22End: 2027-08-25Updated: 2026-03-02

Lot-to-lot Consistency Study of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants From 2 Months of Age

RecruitingNCT07348692

SanofiHealthy Volunteers, Pneumococcal Immunization

Start: 2026-01-20End: 2028-05-29Target: 2195Updated: 2026-04-01